Home/Pipeline/ACE2v2-Fc

ACE2v2-Fc

Acute Respiratory Distress Syndrome (ARDS)

PreclinicalActive

Key Facts

Indication

Acute Respiratory Distress Syndrome (ARDS)

Phase

Preclinical

Status

Active

Company

Cyrus Biotechnology

About Cyrus Biotechnology

Cyrus Biotechnology is a private, preclinical-stage biotech leveraging a proprietary computational protein design platform to discover and develop novel biologics. The company has validated its platform through over 30 discovery programs with partners and is advancing a focused internal pipeline targeting large markets in autoimmune diseases. Its core strategy involves computationally optimizing natural proteins, such as enzymes and cytokines, to create therapeutics with superior pharmacological properties.

View full company profile

Therapeutic Areas

Autoimmune Diseases Gastrointestinal Diseases Metabolic Disorders Acute Respiratory Distress Syndrome (ARDS)

Other Acute Respiratory Distress Syndrome (ARDS) Drugs

Drug	Company	Phase	Status
MultiStem	Athersys	Phase 3	Active (subject to funding)
BXT-25	BioXyTran	Preclinical	Active
Bioengineered Surfactant Program	BioSuperior	Pre-clinical	Active
FX06	F4 Pharma	Phase 1/2	Active
AVM0703	AVM Biotechnology	Pre-clinical / Research	Active
GEn-1124	GEn1E Lifesciences	Phase 2	Active
AZM-152	Azome Therapeutics	Pre-clinical	Active
Zelpultide Alfa	Airway Therapeutics	Pre-clinical/Research	Active
ALT-100 mAb	Aqualung Therapeutics	Phase 2a	Active
RP-323	PhorMed	Phase 2	Active
Research Grant: Effect of volatile sedation on spontaneous breathing in ARDS	Sedana Medical	Investigator-Initiated Trial	Active
Research Grant: Effects of sevoflurane on lung water in ARDS	Sedana Medical	Investigator-Initiated Trial	Active